+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Human Growth Hormone Treatment & Drugs Market 2022-2032

  • PDF Icon

    Report

  • 301 Pages
  • March 2022
  • Region: Global
  • Future Market Insights
  • ID: 5595721
A recent market study published on the market offers global industry analysis for 2014-2021 & opportunity assessment for 2022–2032. The study offers a comprehensive assessment of the more important market dynamics.

After conducting thorough research on the historical and current growth parameters of the Human Growth Hormone Treatment & Drugs Market, the growth prospects of the market are obtained with maximum precision.

Market Segmentation


The Human Growth Hormone Treatment & Drugs Market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.

By Route of Administration

  • Subcutaneous
  • Intramuscular
  • Intravenous
  • Oral

By Application

  • Growth Hormone Deficiency
  • Turner Syndrome
  • Idiopatich Short Stature (ISS)
  • Prader-Willi Syndrome (PWS)
  • Other Applications

By Distribution Channel

  • Hospital Pharmacy
  • Speciality Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa (MEA)

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
5.1. Introduction/Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032
5.3.1. Subcutaneous
5.3.2. Intramuscular
5.3.3. Intravenous
5.3.4. Oral
5.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021
5.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032
6. Global Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
6.1. Introduction/Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
6.3.1. Hospital Pharmacy
6.3.2. Speciality Pharmacy
6.3.3. Retail Pharmacy
6.3.4. Online Pharmacy
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
7. Global Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Application
7.1. Introduction/Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2022-2032
7.3.1. Growth Hormone Deficiency
7.3.2. Turner Syndrome
7.3.3. Idiopatich Short Stature(ISS)
7.3.4. Prader-Willi Syndrome (PWS)
7.3.5. Other Applications
7.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021
7.5. Absolute $ Opportunity Analysis By Application, 2022-2032
8. Global Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.1.3. Rest of North America
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Route of Administration
9.3.3. By Distribution Channel
9.3.4. By Application
9.4. Key Takeaways
10. Latin America Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Route of Administration
10.3.3. By Distribution Channel
10.3.4. By Application
10.4. Key Takeaways
11. Europe Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Spain
11.2.1.6. Russia
11.2.1.7. BENELUX
11.2.1.8. Rest of Europe
11.2.2. By Route of Administration
11.2.3. By Distribution Channel
11.2.4. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Route of Administration
11.3.3. By Distribution Channel
11.3.4. By Application
11.4. Key Takeaways
12. Asia Pacific Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Rest of Asia Pacific
12.2.2. By Route of Administration
12.2.3. By Distribution Channel
12.2.4. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Route of Administration
12.3.3. By Distribution Channel
12.3.4. By Application
12.4. Key Takeaways
13. Middle East and Africa Human Growth Hormone Treatment & Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Turkey
13.2.1.4. Rest of Middle East and Africa
13.2.2. By Route of Administration
13.2.3. By Distribution Channel
13.2.4. By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Route of Administration
13.3.3. By Distribution Channel
13.3.4. By Application
13.4. Key Takeaways
14. Key Countries Human Growth Hormone Treatment & Drugs Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Route of Administration
14.1.2.2. By Distribution Channel
14.1.2.3. By Application
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Route of Administration
14.2.2.2. By Distribution Channel
14.2.2.3. By Application
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Route of Administration
14.3.2.2. By Distribution Channel
14.3.2.3. By Application
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Route of Administration
14.4.2.2. By Distribution Channel
14.4.2.3. By Application
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Route of Administration
14.5.2.2. By Distribution Channel
14.5.2.3. By Application
14.6. Italy
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Route of Administration
14.6.2.2. By Distribution Channel
14.6.2.3. By Application
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Route of Administration
14.7.2.2. By Distribution Channel
14.7.2.3. By Application
14.8. U.K.
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Route of Administration
14.8.2.2. By Distribution Channel
14.8.2.3. By Application
14.9. Spain
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Route of Administration
14.9.2.2. By Distribution Channel
14.9.2.3. By Application
14.10. Russia
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Route of Administration
14.10.2.2. By Distribution Channel
14.10.2.3. By Application
14.11. BENELUX
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Route of Administration
14.11.2.2. By Distribution Channel
14.11.2.3. By Application
14.12. China
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Route of Administration
14.12.2.2. By Distribution Channel
14.12.2.3. By Application
14.13. Japan
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Route of Administration
14.13.2.2. By Distribution Channel
14.13.2.3. By Application
14.14. South Korea
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Route of Administration
14.14.2.2. By Distribution Channel
14.14.2.3. By Application
14.15. GCC Countries
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Route of Administration
14.15.2.2. By Distribution Channel
14.15.2.3. By Application
14.16. South Africa
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Route of Administration
14.16.2.2. By Distribution Channel
14.16.2.3. By Application
14.17. Turkey
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Route of Administration
14.17.2.2. By Distribution Channel
14.17.2.3. By Application
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Route of Administration
15.3.3. By Distribution Channel
15.3.4. By Application
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Ankebio Co.Ltd
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.1.5.2. Product Strategy
16.1.1.5.3. Channel Strategy
16.1.2. Eli Lilly & Company
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.2.5.2. Product Strategy
16.1.2.5.3. Channel Strategy
16.1.3. Emd Serono
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.3.5.2. Product Strategy
16.1.3.5.3. Channel Strategy
16.1.4. Ferring Pharmaceuticals
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.4.5.2. Product Strategy
16.1.4.5.3. Channel Strategy
16.1.5. Genentech Inc
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.5.5.2. Product Strategy
16.1.5.5.3. Channel Strategy
16.1.6. Gene Science Pharmaceutical Co Ltd
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.6.5.2. Product Strategy
16.1.6.5.3. Channel Strategy
16.1.7. Ipsen
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.7.5.2. Product Strategy
16.1.7.5.3. Channel Strategy
16.1.8. LG Life Sciences
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.8.5.2. Product Strategy
16.1.8.5.3. Channel Strategy
16.1.9. Merck KGaA
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.9.5.2. Product Strategy
16.1.9.5.3. Channel Strategy
16.1.10. Novo Nordisk
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.10.5.2. Product Strategy
16.1.10.5.3. Channel Strategy
17. Assumptions & Acronyms Used18. Research Methodology

Companies Mentioned

  • Ankebio Co. Ltd, Eli Lily & Company
  • Emd Serono
  • Ferring Pharmaceuticals
  • Genentech Inc.
  • General Science Pharmaceutical Co Ltd
  • Isenberg
  • Lg Life Sciences
  • Merck Kgaa
  • Novartis Nordisk